CDK1 and ovarian carcinoma: Notably, our study is among the first to propose Naringin as a natural compound capable of simultaneously targeting CDK1 and WEE1, based on both docking affinity and dynamic binding stability—an aspect not explored in prior ovarian cancer studies.